In xenograft models (e.g. prostate cancer, osteosarcoma), sulforaphane leads to growth retardation, inhibition of HDAC activity, and increase in acetylated H3 and H4 levels (64, 69). This evidence concerns the gene HDAC9 and prostate carcinoma.